Member Info for LiveLongnProsper

@desert. Revenue just short of ~$5m for last reported quarter, but net loss (~$25m).

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001811764/000181176423000038/pnt-20230630.htm

Balance sheet looks OK, so think Lily got a good deal – a number of ‘collaborations’ and ‘partnerships’ to factor in though, so (as with CanSEEK™) not all future revenue to Lily.

GLA

Whether CanSEEK™ or other approach to targeting, radiotherapy really does need to need to be highly targeted. The alpha, beta or gamma emissions from the radio isotopes being ‘transported’ through the body in the form of radioligands are not neutralised by the ligand molecule, the radiation just keeps on being emitted (determined by the isotope half-life) and so risks tissue, cell, DNA damage etc. You can’t turn the radiation off – unlike the inert state of ‘transported’ chemotherapy, for example Prodoxorubicin with AVA6000. Add in the need for nearby and near real-time manufacturing, it just adds to the challenge. Just highlights the enormous potential of the pre|CISIONTM platform with, potentially, a range of Chemo/MMAE warheads.

Anyway, suspect Lily getting a bit worried by the Novartis pipeline …

https://www.novartis.com/research-development/novartis-pipeline?search_api_fulltext=&field_therapeutic_area%5B%5D=2771

Now which other BP have oncology pipeline ‘deficits’?

GLA

Of 35 producing wells a total of -116 days lost against a max of 31x35=1085.

Plus 1 well with 0 production on 0 days in Aug that was producing in Jul.

The lost days are somewhat ‘skewed’ to the larger wells, but the real problem is that historical levels of production have not been achieved, which suggests that GGS / injection being deployed with caution.

GLA

To add some more detail.

Top 7 (those over 2000) …

BFU 32-27V, 3405

BFU 34-20V, 3198 (down -1288)

BFU Fed 11-22V, 3123

BFU 44-22V, 2903

BFU FED 32-21V, 2483

BFU 44-21V, 2176

BFU 21-35-76 ST A SN 3H, 2066

Wells that produced 150 barrels more in Aug vs July …

BFU 21-35-76 ST A SN 3H, 2066 +771 on 21 days (plus 4694 gas and 4606 water, so ‘activity’)

BFU 21-34V, 835 +571 on 31 days (31 days in July also, so good increase)

BFU 23-27V, 1464 +169 on 23 days (plus 11651 gas, so something happening)

BFU 14-23V, 927 +153 on 29 days

BFU 23-14V, 670 + 151 on 24 days

11 more wells with increases totalling +645. Overall vs Jul, 16 wells higher, total gained +2460.

Wells that produced 150 barrels less in Aug vs July …

BFU 34-20V, 3198 -1288 on -7 fewer (24) days (plus 13902 gas!)

BFU FEDERAL 41-34H, 720 -856 on 31 days

BFU FED 11-28V, 620 -515 on -14 fewer (17) days

BFU FED 21-21V, 563 -462 on -8 fewer (21) days

COLE CREEK 31-17, 0, -428 on 0 days (so not producing)

BFU FED 33-23V, 1072 -379 on -1 fewer days

BFU Fed 41-20V, 290 -187 on 10 fewer (19) days

13 more wells with decrease totalling -641. Overall vs Jul, 20 wells lower, total lost -4756.

Reconciliation, July 37,831 plus +2460 less – 4756 = 35,535

Problem (obvious) more losers with bigger losses, hope that this is indicative of GGS commissioning / tuning and a lot of other field improvement activity. Would be good to get a ‘flash’ report on September.

GLA

@Codej, agree. Very simple arithmetic), expect more from Coris and Launch. Interesting to see what Tony Gardiner has to say about DX co.'s.

GLA

From slide 8 …

“…giving a cash runway into H2 2024.”

Really simple ‘check’ of numbers – £41.78m end-2022 less £25.97m end-H1 = £15.81m net cash spent in 6 months, or £2.635m / month, add in a few more expensive staff and let’s say £3m / month, so realistically need to sort funding before end-Q1 24.

So time to publish peer-reviewed data, and therefore plenty of time to sort out (non-dilutive) funding.

GLA

Courtesy @Mstambo999 from twiX …

https://twitter.com/hashtag/AVCT?src=hashtag_click&f=live

Nice design, wood, granite (effect), plants, looks like we’re ‘green’ then.

(Is that David Wilson peeking out from the back, perhaps he’s now ‘chief stand designer’?).

GLA

In fact potentially so good it’s not just about delivering Chemo (Dox plus others) to the tumour safely.

7 Jan 2021 License Agreement with POINT Biopharma Inc.

“The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.”

Given the agreement with POINT is non-exclusive, after the first radiopharmaceutical, will we see other companies interested in licensing pre|CISIONTM in the same way POINT has for CanSEEK™?

Novartis and POINT) seem to be ‘leading the pack’?

Do we actually have to wait for POINT to confirm the first radioligand to be delivered by CanSEEK™? Or are there licensing opportunities to be had now for pre|CISIONTM delivery of radioligands?

GLA

For info …

https://www.takedaoncology.com/news/news-releases/takeda-receives-positive-CHMP-opinion-for-ADCETRIS-for-the-treatment-of-adult-patients-with-previously-untreated-CD30-stage-III-hodgkin-lymphoma-in-combination-with-AVD/

Takeda Phase 3 for ADCETRIS® (brentuximab vedotin) – note “in combination with doxorubicin ..”.

OK, looks very positive, but read down for the “Special Warnings and Precautions”.

Still waiting for Takeda to licence pre|CISION™ for AVA3996/2727D, given Velcade (bortezomib) off patent.

GLA

Https://www.youtube.com/watch?v=C7HAHG0-ncc

From PMH Capital on twiX – Avacta from ~6:30.

GLA

POO matters. Global oil supply matters. One is going up, the other seems to be going down ...

BBC Business Report just saying that “global oil prices have reached highest level for more than 10 months”, driven by production cuts in Saudi and Russia. “IEA has warned of a significant supply shortfall by the end of the year”.

Meanwhile COPL said (6 Sept RNS) – “The Company is focused on delivering production results in Q4 2023 …”.

Great timing.

GLA

This is a very good question.

Are the continuing patients still under the original trial protocol?

Have they exceeded the planned number of cycles?

Has the 3-weekly dosing level been increased to C6 level?

Etc. Many questions. Hope for some ‘illumination’ soon.

GLA

New 'insight' from Hurst - IPO. What, where, when, source, please @Hurst10.

GLA

US EIA short-term energy outlook, updated 12 Sept, also notes the continuing Saudi oil production cut …

https://www.eia.gov/outlooks/steo/report/index.php

Forecast Brent @ ~$93 through Q4/23 with a slight easing to average ~$88 in 2024 (note – WTI usually ~$4 lower).

Also forecasting an increase in US domestic oil production in 2024 (vs 2023).

6 Sept RNS states – “The Company is focused on delivering production results in Q4 2023 …”.

No hedge, oil price forecast to go up in Q4, US production to increase in 2024 (where from?). And, if you look through the report, US CO2 emissions remaining ‘stubbornly’ high – anyone help here?

GLA

Trial design seemed to be ‘modified’ during the presentation. Who knows what the plan is now?

Slide 10 – ‘Indicative Trial Design’, 2 groups of ‘Up to 20 Patients’ at ‘Dose 1’ and ‘Dose 2’ of AVA6000 vs ‘15-20 Patients Doxorubicin’.

Slide 21, 27 – ‘2 AVA6000 dose levels for Phase 1b’, but 2 x 24 patients AVA6000 and 12 Doxorubicin.

GLA

TTI-621 (Pfizer) …

https://www.pharmaceutical-technology.com/data-insights/tti-621-pfizer-follicular-lymphoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-234742&utm_campaign=recommended-articles

TTI-621-03: A phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS) …

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS11593

MSK …

https://www.mskcc.org/cancer-care/clinical-trials/21-407

Investigator - Sujana Movva …

https://www.mskcc.org/cancer-care/doctors/sujana-movva#about_specialties

Clinical Trials Co-Investigated by Dr. Movva - A Phase 1a Study of AVA6000 in People with Solid Tumors ..

https://www.mskcc.org/cancer-care/clinical-trials/22-428

Safety and effects of TTI-621 in combination with doxorubicin …

https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/792ae267-45a6-4ae0-a0b0-158f4a2d3cfd/The%20safety%20and%20effects%20of%20TTI-621%20in%20combination%20with%20doxorubicin%20in%20people%20living%20with%20leiomyosarcoma.pdf

“The most severe side effects were thought to be caused by doxorubicin …”.

No doubt Dr Movva knows about a (much) better alternative to ‘straight’ dox?

Wonder how many more ‘combo’ therapies would benefit from AVA6000?

GLA

WTI at ~$87.50 now but …

https://edition.cnn.com/2023/09/06/business/oil-price-goldman-sachs/index.html

Interesting and well summarised article on the tension between Saudi / Russia wanting higher oil prices and President Biden’s desire to keep US gasoline prices down.

Looks like a win-win for COPL – oil price goes up to $107 (Goldman Sachs) or US domestic production goes up.

GLA

From the RNS.

"Alistair Smith, CEO .."?

Someone in trouble this morning.

GLA

Https://webfiles.thecse.com/08_CSE_Form_7_-_Monthly_Progress_Report_-_Aug_2023.pdf?5utsQWTvSc803h6ZUEF8xebNfdTFmgic

August vs July …

A few more shares in issue 699m vs 681m.

5 Nothing about the JV (was reported in July).

14 Where the additional shares came from.

Nothing about the GGS upgrade, production, etc. Absolutely minimalistic!

Everyone working hard on JV (I hope).

GLA

AGM presentation 28th June 2023.

Slide 10 – ‘Indicative Trial Design’, 2 groups of ‘Up to 20 Patients’ at ‘Dose 1’ and ‘Dose 2’ of AVA6000 vs ‘15-20 Patients Doxorubicin’.

Slide 21, 27 – ‘2 AVA6000 dose levels for Phase 1b’, but 2 x 24 patients AVA6000 and 12 Doxorubicin.

Slide 26 – suggests a Biologically Effective Dose (BED) at Cohort 3+ dosing level, I.e. 160 mg/m2 AVA6000.

Cohort 5 Tumour Biopsy Data results, peer group reviewed, published, awaited. Not to mention Cohort 6 update.

Phase 1b design looks ‘fluid’. Dose 1 – some level of BED? Dose 2 – at MTD if found?

GLA